EPrints@IIT Delhi >
Faculty Research Publicatons  >
Biomedical Engineering [CBME] >

Please use this identifier to cite or link to this item: http://eprint.iitd.ac.in/handle/2074/394

Full metadata record

DC FieldValueLanguage
dc.contributor.authorGuha, Sujoy K-
dc.contributor.authorGulshanjit Singh-
dc.contributor.authorAnsari, Shirfuddin-
dc.contributor.authorSudheer Kumar-
dc.contributor.authorSrivastava, Anil-
dc.contributor.authorKoul, Veena-
dc.contributor.authorDas, H C-
dc.contributor.authorMalhotra, R L-
dc.contributor.authorDas, S K-
dc.identifier.citationContraception, 56, 245-250en
dc.description.abstractFollowing up on an earlier clinical trial demonstrating the safety of an intra-vas deferens injection of a contraceptive drug named Risug, comprised of styrene maleic anhydride (SMA) in a solvent vehicle of dimethylsulphoxide (DMSO),a study to assess the contraceptive effectiveness of a specific dose (60 mg) of SMA bilaterally was planned and implemented, Male subjects and their wives with normal reproductive profiles were the volunteer subjects. The wives were not using any contraceptives. The results re-confirm the safety and show that for a period of at least 1 year, the treatment leads to azoospermia in the male and gives pregnancy protection.en
dc.format.extent221823 bytes-
dc.subjectinjectable male contraceptiveen
dc.subjectstyrene maleic anhydrideen
dc.subjectpregnancy protectionen
dc.titlePhase II clinical trial of a vas deferens injectable contraceptive for the maleen
Appears in Collections:Biomedical Engineering [CBME]

Files in This Item:

File Description SizeFormat
guhapha97.pdf216.62 kBAdobe PDFView/Open
View Statistics

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback